After reports of “two serious and potentially life-threatening medical conditions,” the FDA this week issued a consumer alert for osteoarthritis capsule Limbrel. The alert: Don’t take it. And that came as a surprise to Limbrel manufacturer Primus Pharmaceuticals. “They visited our offices on Nov. 8, as they said in the alert, then spent four days...